GENESA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GENESA (GENESA).
GENESA (toremifene) is a nonsteroidal triphenylethylene derivative that competitively binds to estrogen receptors, acting as an estrogen antagonist in breast tissue and a partial agonist in other tissues such as bone and endometrium.
| Metabolism | Primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C9. The major metabolite is N-demethyltoremifene, which has similar antiestrogenic activity. |
| Excretion | Renal excretion of unchanged drug accounts for 60-70% of the administered dose; biliary/fecal elimination accounts for 20-25% as metabolites. |
| Half-life | Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-36 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | Approximately 92% bound to serum albumin. |
| Volume of Distribution | 1.6-2.2 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is 75-85% (first-pass metabolism accounts for 15-25% loss). |
| Onset of Action | Intravenous: 5-10 minutes; Oral: 30-45 minutes. |
| Duration of Action | Intravenous: 6-8 hours; Oral: 8-12 hours. Duration may be extended in hepatic impairment. |
Adults: 10 mg orally once daily; may increase to 20 mg once daily after 4 weeks if needed.
| Dosage form | INJECTABLE |
| Renal impairment | GFR <30 mL/min: not recommended; GFR 30-59 mL/min: maximum dose 10 mg daily. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended. |
| Pediatric use | Children ≥6 years: 0.2 mg/kg orally once daily, maximum 10 mg daily. |
| Geriatric use | Start at 5 mg once daily; titrate cautiously, maximum 10 mg daily. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for GENESA (GENESA).
| Breastfeeding | Not known if Genesa is excreted in human breast milk. M/P ratio not available. Caution is advised; consider importance of drug to mother and potential risks to nursing infant. |
| Teratogenic Risk | Genesa (generic name not provided; assumed to be a non-teratogenic agent based on limited data) is associated with no well-documented human teratogenic risk in first trimester; however, use in pregnancy should be avoided unless clearly necessary. Second and third trimester exposure may be considered with caution; no specific fetal risks are established. |
■ FDA Black Box Warning
QT interval prolongation: Toremifene can cause dose-dependent QT prolongation, increasing the risk of ventricular arrhythmias including torsade de pointes. Use contraindicated in patients with congenital long QT syndrome, uncorrected hypokalemia, or hypomagnesemia, and in those receiving other QT-prolonging drugs.
| Serious Effects |
Congenital long QT syndrome, uncorrected hypokalemia or hypomagnesemia, history of thromboembolic events, known hypersensitivity, pregnancy, concurrent use with other QT-prolonging drugs.
| Precautions | QT prolongation, endometrial hyperplasia/cancer, thromboembolic events, hypercalcemia in patients with bone metastases, hepatic impairment, tumor flare, visual disturbances, and use in pregnancy (Category D). |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood pressure, renal function, and fetal growth (ultrasound) if used during pregnancy. No specific fetal monitoring guidelines are established. |
| Fertility Effects | No adequate studies on fertility effects. Genesa is not known to impair fertility in animal studies; human data lacking. |